India is an increasingly attractive destination for R&D activities in the pharmaceutical and biotechnology industry. Being an emerging market,
February 15, 2007 (Press Release) --
India: Pharmaceutical and Biotechnology Opportunities
India is an increasingly attractive destination for R&D activities in the pharmaceutical and biotechnology industry. Being an emerging market, companies face a number of unique hurdles before entering this lucrative region.
The report provides an overview of the Indian pharma and biotech market, and answers the following key questions:
Who are the key players in the Indian pharmaceutical market?
How has the Indian regulatory environment changed?
What R&D collaborative opportunities are available?
How can companies engage with India for collaboration?
What are the leading R&D companies in India doing in collaborative R&D?
Readers will gain an analysis of the regulatory environment, insights into collaborative opportunities and detailed information on the key companies, clusters and government initiatives.
This report is a valuable resource for use by all those developing company strategy and direction in this key emerging market.
'India: Pharmaceutical and biotechnology opportunities' is based on the December 2004 report 'India: The emerging R&D collaborative opportunity'. The new report includes additional sections on the Indian Patents Act 2005, the Indian pharmaceutical policy, an overview of Department of Biotechnology initiatives, including details of biotechnology parks, and an all-new set of profiles on life science research institutes.
The profiles section of 'India: Pharmaceutical and biotechnology opportunities' contains updated profiles and contact details on key companies.
Reasons to purchase (USPs and key questions answered)
This report will provide the reader with an insight into the Indian pharmaceutical market and the emerging R&D collaborative opportunities on offer.
The report answers the following key questions about the Indian R&D collaborative opportunity:
Who are the key players in the Indian pharmaceutical market?
How has the Indian regulatory environment changed?
What R&D collaborative opportunities are available?
How to engage with Indian companies for collaboration?
What are the leading R&D companies in India doing in collaborative R&D?
Report scope
Scope of report:
An overview of the Indian pharmaceutical industry
Key players in the Indian pharmaceutical market
An analysis of the regulatory environment and its implications for R&D
Collaborative R&D opportunities in India
Engagement models for licensing and purchasing innovation and for contracting research services
Approaches to collaboration in NCE/NDDS, biopharma, drug discovery, biotechnology, bioinformatics, and clinical research
Profiles of leading R&D companies—NCE/DDS, bioinformatics, biopharma, drug discovery, clinical research
Profiles of life science research institutes
Regional Government initiatives
India is an increasingly attractive destination for R&D activities in the pharmaceutical and biotechnology industry. Being an emerging market, companies face a number of unique hurdles before entering this lucrative region.
The report provides an overview of the Indian pharma and biotech market, and answers the following key questions:
Who are the key players in the Indian pharmaceutical market?
How has the Indian regulatory environment changed?
What R&D collaborative opportunities are available?
How can companies engage with India for collaboration?
What are the leading R&D companies in India doing in collaborative R&D?
Readers will gain an analysis of the regulatory environment, insights into collaborative opportunities and detailed information on the key companies, clusters and government initiatives.
This report is a valuable resource for use by all those developing company strategy and direction in this key emerging market.
'India: Pharmaceutical and biotechnology opportunities' is based on the December 2004 report 'India: The emerging R&D collaborative opportunity'. The new report includes additional sections on the Indian Patents Act 2005, the Indian pharmaceutical policy, an overview of Department of Biotechnology initiatives, including details of biotechnology parks, and an all-new set of profiles on life science research institutes.
The profiles section of 'India: Pharmaceutical and biotechnology opportunities' contains updated profiles and contact details on key companies.
Reasons to purchase (USPs and key questions answered)
This report will provide the reader with an insight into the Indian pharmaceutical market and the emerging R&D collaborative opportunities on offer.
The report answers the following key questions about the Indian R&D collaborative opportunity:
Who are the key players in the Indian pharmaceutical market?
How has the Indian regulatory environment changed?
What R&D collaborative opportunities are available?
How to engage with Indian companies for collaboration?
What are the leading R&D companies in India doing in collaborative R&D?
Report scope
Scope of report:
An overview of the Indian pharmaceutical industry
Key players in the Indian pharmaceutical market
An analysis of the regulatory environment and its implications for R&D
Collaborative R&D opportunities in India
Engagement models for licensing and purchasing innovation and for contracting research services
Approaches to collaboration in NCE/NDDS, biopharma, drug discovery, biotechnology, bioinformatics, and clinical research
Profiles of leading R&D companies—NCE/DDS, bioinformatics, biopharma, drug discovery, clinical research
Profiles of life science research institutes
Regional Government initiatives
Email
Print
SPAM
